Drug intelligence / Profile preview

prostaglandin E1 + prostaglandin I2

Development stage
Preclinical
Lead developer
Pfizer
Modality
Small Molecules
Administration
Intra-arterial, Intracavernosal, Intraurethral, Intravenous
01

Overview

This is a combination of two naturally occurring prostaglandins—prostaglandin E1 (PGE1, also known as alprostadil) and prostaglandin I2 (PGI2, also known as prostacyclin or epoprostenol). Both are potent vasodilators with distinct but complementary mechanisms. Prostaglandin E1 acts primarily by relaxing vascular smooth muscle, leading to vasodilation and inhibition of platelet aggregation; it is used clinically for erectile dysfunction and to maintain ductus arteriosus patency in neonates with congenital heart defects[2][3][4]. Prostaglandin I2 (prostacyclin) is a strong vasodilator and inhibitor of platelet aggregation, widely used in the management of pulmonary arterial hypertension[4]. The combination may be considered for synergistic effects on vascular tone or platelet function but does not have a widely recognized brand name or fixed-dose formulation.

Other names
prostaglandin E1 and prostacyclinalprostadil + epoprostenolPGE1 + PGI2
02

Targets

PTGIR (Prostanoid IP Receptor)PTGER1 (Prostaglandin E Receptor 1)

Beyond the preview

Go deeper on prostaglandin E1 + prostaglandin I2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on prostaglandin E1 + prostaglandin I2.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call